Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05476926 · ClinicalTrials.gov registry record
A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products
A clinical trial of Diabetic Macular Edema and Neovascular Age-related Macular Degeneration, sponsored by Hoffmann-La Roche.
- Active
- Registry status
- 6,000
- Enrollment target
- 20
- Study locations
NCT05476926 is a study of Diabetic Macular Edema and Neovascular Age-related Macular Degeneration that is active but no longer recruiting, run by Hoffmann-La Roche. The registered enrollment target is 6,000 participants, above the 3,699-participant average among 63 other Diabetic Macular Edema trials with a reported enrollment target (62% higher). The trial reports 20 study locations across 15 states.
The verdict
NCT05476926, a study of Diabetic Macular Edema and Neovascular Age-related Macular Degeneration, is active but no longer recruiting, sponsored by Hoffmann-La Roche.
- ACTIVE NOT RECRUITING
- Registry status
- 6,000 participants
- Enrollment target
- 20
- Study locations
Study Summary
The VOYAGER study is a primary data collection, non-interventional, prospective, multinational, multicenter study. It is designed to collect real-world, long-term data to explore long-term effectiveness, safety, clinical insights, treatment patterns, and factors driving the treatment decisions among patients being treated with specified Roche ophthalmology products in approved retinal indications (Faricimab for neovascular age-related macular degeneration \[nAMD\], diabetic macular edema \[DME\], and retinal vein occlusion; Port Delivery System with Ranibizumab for nAMD) in routine clinical practice. This study will not provide or make recommendations on use of any products including Roche products; treatment decisions will be determined by the treating physician and must be made independently to the decision to participate in this study. Participation in this study will not change or influence a patient's standard of care in any way.
Conditions Studied
Interventions
- DRUG Faricimab
- COMBINATION_PRODUCT Port Delivery System with Ranibizumab
Study Locations (20)
California
- California Eye Specialists Medical group Inc. - Pasadena
- Retinal Consultants Medical Group - Sacramento
Florida
- Advanced Research - Coral Springs
- Retina Specialty Institute - Pensacola
Illinois
- University Retina and Macula Associates, PC - Lemont
- Springfield Clinic, Llp - Springfield
Texas
- Brown Retina Institute - San Antonio
- Retina Center of Texas - Southlake
Virginia
- Piedmont Eye Center - Lynchburg
- Wagner Macula and Retina Center - Norfolk
Arizona
- Retinal Research Institute, LLC - Phoenix
Kentucky
- Retina Associates of Kentucky - Lexington
Maryland
- Cumberland Valley Retina Consultants PC - Hagerstown
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6,000 participants |
| Start Date | 2022-11-21 |
| Est. Completion | 2027-11-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05476926
The ClinicalTrials.gov registry entry for NCT05476926 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 6,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 3,699-participant average among 63 other Diabetic Macular Edema trials with a reported enrollment target (62% higher). The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 6 conditions, with Diabetic Macular Edema appearing as the primary indexed condition, and to 2 interventions - of which Faricimab is the first listed.
NCT05476926 reports 20 study locations spanning 15 distinct geographic areas - top geographies include California, Florida, Illinois.
Frequently Asked Questions
What is clinical trial NCT05476926 about?
NCT05476926 is a clinical study titled "A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products". The VOYAGER study is a primary data collection, non-interventional, prospective, multinational, multicenter study. It is designed to collect real-world, long-term data to explore long-term effectiveness, safety, clinical insights, treatment patterns, and factors driving the treatment decisions among...
What is the current status of trial NCT05476926?
This trial is currently active not recruiting. The enrollment target is 6,000 participants. The study started on 2022-11-21. Estimated completion is 2027-11-30.
What conditions does trial NCT05476926 study?
This clinical trial studies the following conditions: Diabetic Macular Edema, Neovascular Age-related Macular Degeneration, Retinal Vein Occlusion, Branch Retinal Vein Occlusion, Central Retinal Vein Occlusion.
What interventions are being tested in trial NCT05476926?
The interventions under investigation include: Faricimab (DRUG), Port Delivery System with Ranibizumab (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT05476926?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05476926 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Illinois, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetic Macular Edema
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluation of K9 in Subjects With Diabetic Macular Edema (DME)
RECRUITING · Phase 1
-
EC-104 Intravitreal Implant for the Treatment of Diabetic Macular Edema
RECRUITING · Phase 1
-
Phase I Study to Assess the Safety and Efficacy of OCU200 for Center-Involved Diabetic Macular Edema (DME)
RECRUITING · Phase 1
-
CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME
RECRUITING · Phase 3
-
A Study to Evaluate Efficacy, Safety & Pharmacokinetics of the Port Delivery System (PDS) With Ranibizumab in Participants With Diabetic Macular Edema (DME) Compared With Intravitreal Ranibizumab; A Substudy to Evaluate the Safety of Re-implanting the PDS With Ranibizumab in Participants With DME
RECRUITING · Phase 3
-
COMO: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME
RECRUITING · Phase 3
Explore more on PlainTrial
Diabetic Macular Edema
All registered trials for this condition
Neovascular Age-related Macular Degeneration
All registered trials for this condition
Arizona
All trials with a study site in Arizona
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.